Clinical Trial Update: (VELA) Study of BLU-222 in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study of BLU-222 in advanced solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Carcinosarcoma
• Endometrial Cancer
• Esophageal Adenocarcinoma
• Gastric Cancer
• Ovarian Cancer

Drugs mentioned

• BLU-222

Snippet

Sponsor: Blueprint Medicines Corporation | Conditions: Advanced Solid Tumors, HR+ Breast Cancer | Phase 1 | Status: TERMINATED